Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis.
Future Oncol
; 15(12): 1397-1406, 2019 Apr.
Article
em En
| MEDLINE
| ID: mdl-30734573
ABSTRACT
Aim:
Elevated serotonin in patients with neuroendocrine tumors (NETs) may impact heart failure incidence but a quantitative relationship has not been established. Materials &methods:
Systematic review and meta-analysis of studies assessing 24-h urinary 5-hydroxyindoleacetic acid (u5-HIAA) and mortality in patients with NETs (2007-2017) with a primary outcome of 1-year mortality risk and 24-h u5-HIAA.Results:
We identified 1715 records of which 12 studies including 755 patients (3442 person-years with 376 deaths) were eligible for meta-analysis. Mean u5-HIAA was 149.2 mg/24 h (standard deviation 96.6) and mortality was 13.0%. The meta-regression equation showed an 11.8% (95% CI 8.9-17.0%; I2 = 93.0%) increase in 1-year mortality for every ten-unit increase in u5-HIAA.Conclusion:
Serotonin measured by its metabolite u5-HIAA is predictive of 1-year all-cause mortality in patients with NETs.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pancreáticas
/
Neoplasias Gástricas
/
Doença Cardíaca Carcinoide
/
Tumor Carcinoide
/
Serotonina
/
Biomarcadores Tumorais
/
Tumores Neuroendócrinos
/
Neoplasias Intestinais
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article